Trial reportCirculation. Cardiovascular quality and outcomes2011
Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.
Trial report in Circulation. Cardiovascular quality and outcomes, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 71 citations in OpenAlex.
- Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).Journal of the American Heart Association · 2017Trial
- Hearts apart: exploring sex disparity in the global and regional burden of ischemic heart disease; a systematic analysis from the global burden of disease study 1990-2021.BMC cardiovascular disorders · 2025Article
- Differences in Risk Factors for Coronary Atherosclerosis According to Sex.Journal of lipid and atherosclerosis · 2024Review
- Editorial: Sex differences and cardiovascular therapeutics.Frontiers in cardiovascular medicine · 2024Article
- Sex Differences in Coronary Artery Disease: Insights From the KoRean wOmen'S chest pain rEgistry (KoROSE).Korean circulation journal · 2023Review
- Natural language processing to identify reasons for sex disparity in statin prescriptions.American journal of preventive cardiology · 2023Article
- Gender disparities in prevalence by diagnostic criteria, treatment and mortality of newly diagnosed acute myocardial infarction in Korean adults.Scientific reports · 2023Article
- Challenges in Optimizing Lipid Management in Women.Cardiovascular drugs and therapy · 2022Review
- High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.Journal of the American College of Cardiology · 2022Article
- Review of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years.Reviews in cardiovascular medicine · 2022Article
- Retrospective Comparison of Appropriate Statin Use Between Patients With Diabetes in the Primary Care Setting Managed by Pharmacists or Internal Medicine Providers.Diabetes spectrum : a publication of the American Diabetes Association · 2019Article
- Underutilization of Statin Therapy for Secondary Prevention of Cardiovascular Disease Among Older Adults.Population health management · 2019Article
- Gender Differences in Ischemic Cardiomyopathy.Current atherosclerosis reports · 2018Review
- Sex Differences in the Coronary System.Advances in experimental medicine and biology · 2018Review
- Primary and secondary prevention of ischemic heart disease in women.Current atherosclerosis reports · 2015Review
- Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease.The American journal of the medical sciences · 2014Article
- Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies.PloS one · 2014Article
- Sex differences in endothelial function of aged hypertriglyceridemic rats - effect of atorvastatin treatment.Interdisciplinary toxicology · 2012Article
- Therapy for stable angina in women.P & T : a peer-reviewed journal for formulary management · 2012Article
- Impact of predictors upon the reduction of lipid parameters in family medicine practice.Sao Paulo medical journal = Revista paulista de medicinaArticle
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundDespite the known benefit of intensive statin therapy for reducing future cardiovascular events, its effectiveness in women has been questioned by some. METHODS AND
resultsIn the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial, 911 (21.9%) women and 3251 (78.1%) men were randomized to intensive statin (atorvastatin 80 mg) versus standard therapy (pravastatin 40 mg) therapy for a median duration of 2.1 years. The primary end point was death, myocardial infarction, unstable angina; revascularization (occurring after 30 days); or stroke. Safety end points included elevations in liver function tests, creatine kinase, and myalgias/myositis. Women had a reduction in low-density lipoprotein (LDL) of 42.8% from baseline at 30 days (to a median of 60 mg/dL) in the intensive therapy arm, with 88.8% reaching the LDL goal of <100 mg/dL and 65.0% of <70 mg/dL, compared with a 16.8% reduction in LDL (to a median of 88 mg/dL) in the standard therapy arm. Women receiving intensive statin therapy had a significant 25% relative reduction over standard dose (hazard ratio, 0.75; 95% CI, 0.57 to 0.99; P=0.04) for the primary composite end point compared with a 14% reduction for men (hazard ratio, 0.86; 95% CI, 0.75 to 0.99; P=0.04; P-interaction, 0.38). No differences were observed between sexes for safety (all P-interaction ≥0.11).
conclusionsThis trial provides evidence that both women and men derived benefit from intensive statin therapy after acute coronary syndrome, and thus, sex should not be a factor in determining who should be treated with intensive statin therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.